Nesivine (Oxymetazoline Hydrochloride)

Oxymetazoline is a selective alpha‑1 adrenergic receptor agonist and partial alpha‑2 agonist. By activating these receptors on nasal blood vessels, it causes vasoconstriction, reduces swelling, and opens the nasal passages.

The appropriate dose of Nesivine is determined by a healthcare professional based on the individual’s age, condition severity, and response. Users should follow the prescriber’s instructions or the product label.

Safety data for oxymetazoline in pregnancy and lactation are limited. Women who are pregnant or breastfeeding should consult their physician before using Nesivine to weigh potential benefits against risks.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nesivine’s active ingredient, oxymetazoline, provides rapid vasoconstriction similar to phenylephrine but typically has a longer duration of action. Unlike systemic decongestants, it acts locally, reducing systemic side effects, though prolonged use can cause rebound congestion.

Store Nesivine at ambient temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from moisture and direct sunlight, and keep out of reach of children.

Nesivine is applied as a nasal spray. The user tilts the head slightly forward, inserts the nozzle into one nostril, and sprays the recommended number of sprays while breathing in gently. The process is repeated in the other nostril if required.

Serious risks include elevated blood pressure, severe nasal ulceration, cardiac arrhythmias, and allergic reactions such as rash or swelling. Persistent or worsening symptoms should prompt immediate medical evaluation.

Individuals with known hypersensitivity to oxymetazoline, severe hypertension, recent heart attack, or those using monoamine oxidase inhibitors should avoid Nesivine unless directed by a physician.